Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 9/20 | 0.60 |
| ▸ | CDK4 | P11802 | 4/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 3/20 | 0.53 |
| ▸ | CDK1 | P06493 | 5/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765011 | 0.91 | CDK19 (0.58) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3755334 | 0.90 | CDK19 (0.70) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3762802 | 0.84 | ALK (0.53) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3760568 | 0.83 | CDK2 (0.74) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3762659 | 0.83 | CDK2 (0.56) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3756899 | 0.82 | CDK2 (0.57) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3766961 | 0.81 | CDK2 (0.52) | CDK19ALKCDK2CDK4CCNE1 | |
| SCHEMBL3760761 | 0.81 | CDK2 (0.66) | CDK2CDK4CCNE1IGF1RCDK1 | |
| SCHEMBL3757034 | 0.79 | CDK2 (0.66) | CDK2CDK4CCNE1IGF1RCDK1 | |
| SCHEMBL1787518 | 0.78 | CDK19 (0.72) | CDK19ALKCDK2CCNE1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | CDK19 53/4885ALK 534/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.